FDA wants public input on allowing cannabidiol's use in dietary supplements marketed with compliant claims, unlike the disease claims for CBD supplements made by three firms the agency recently warned.
"I believe these are egregious, over-the-line claims and we won’t tolerate this kind of deceptive marketing to vulnerable patients," FDA Commissioner Scott Gottlieb said of the claims listed in the agency's warning letters to Advanced Spine and Pain
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?